

## ATX7 Polyclonal Antibody

### Description

<b>Product type</b>	Primary Antibody
<b>Code</b>	BT-AP06606
<b>Host</b>	Rabbit
<b>Isotype</b>	IgG
<b>Size</b>	100ul, 50ul, 20ul
<b>Immunogen</b>	Synthesized peptide derived from human protein . at AA range: 260-340
<b>Mol wt</b>	N/A
<b>Species reactivity</b>	Human, Mouse
<b>Clonality</b>	Polyclonal
<b>Recommended application</b>	WB, ELISA
<b>Concentration</b>	1 mg/ml
<b>Full name</b>	Ataxin-7
<b>Synonyms</b>	Ataxin-7 ;Spinocerebellar ataxia type 7 protein

**This product is for research use only, not for use in human, therapeutic or diagnostic procedure.**

### Background

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCA I is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCA II, which always presents with retinal degeneration (SCA7), and ADCA III often referred to as the 'pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmi

### Recommended Dilution

WB: 1: 500 - 1: 2000

ELISA: 1: 5000 - 1: 20000

Not yet tested in other applications.

### Images

No images.

### Storage

-20°C for 1 year